4-苄基-N-苯基哌啶-1-甲酰胺 | 193204-16-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-苄基-N-苯基哌啶-1-甲酰胺
• 英文名称: 4-benzyl-piperidine-1-carboxylic acid phenylamide
• 英文别名: 1-[2-aza-1-oxo-2-phenylethyl]-4-benzylpiperidine；4-benzyl-N-phenylpiperidine-1-carboxamide
• CAS: 193204-16-9
• 化学式: C₁₉H₂₂N₂O
• 分子量: 294.396
• InChiKey: QFRMWZYPOXTWQT-UHFFFAOYSA-N

物化性质

• 沸点：
  497.2±18.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-苄基哌啶 、 异氰酸苯酯 生成 4-苄基-N-苯基哌啶-1-甲酰胺
  参考文献：
  名称：

  Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase

  摘要：

  某些哌嗪基和哌啶基脲类化合物可作为FAAH抑制剂。这些化合物可以用于制备药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、障碍和病况的方法。因此，这些化合物可以用于治疗焦虑、疼痛、炎症、睡眠障碍、进食障碍或运动障碍（如多发性硬化症）。

  公开号：

  US07598249B2

文献信息

• Subtype-selective NMDA receptor ligands and the use thereof
  申请人：Warner-Lambert Co.

  公开号：US06218404B1

  公开（公告）日：2001-04-17

  The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neuro-degenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  该发明涉及亚型选择性NMDA受体配体及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化、亨廷顿病和唐氏综合征在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑、精神病、抽搐、氨基糖苷类抗生素引起的听力损失、偏头痛、慢性疼痛、帕金森病、青光眼、巨细胞病毒性视网膜炎、尿失禁、阿片类药物耐受性或戒断症状，并诱导麻醉，以及增强认知能力。
• PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Apodaca Richard

  公开号：US20100004261A1

  公开（公告）日：2010-01-07

  Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

  某些哌嗪基和哌啶基脲类化合物可用作FAAH抑制剂。这些化合物可以用于制备药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态，障碍和病况的方法。因此，这些化合物可以被用于治疗例如焦虑，疼痛，炎症，睡眠障碍，进食障碍或运动障碍（如多发性硬化症）等疾病。
• 4-(BENZYL)-PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP2937341A1

  公开（公告）日：2015-10-28

  Compounds of formula (I): wherein, Z is -N- or >CH; R1 is -H or -C1-4alkyl; Ar1 is 2-thiazoly, 2-pyridy, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring member with one or two Ra moieties; where each Ra moiety is independently selected from the group consisting of -C1-4alkyl, -C2-4alkenyl, -OH, -OC1-4alkyl, halo -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkyl, -OSO2C1-4alkyl, -CO2C1-4alkyl, -CO2H, -COC1-4alkyl, -N(Rb)Rc, -SO2NRbRc, -NRbSO2R, -C(=O)NRbRc, -NO2, and -CN, wherein Rb and Rc are each independently -H or -C1-4alkyl; and Ar2 is defined in the claims are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

  式(I)化合物：其中，Z 是 -N- 或 >CH；R1 是 -H 或 -C1-4烷基；Ar1 是 2-噻唑基、2-吡啶基、3-吡啶基、4-吡啶基、2-嘧啶基、4-嘧啶基、5-嘧啶基或苯基，各自未被取代或在碳环成员处被一个或两个 Ra 基取代；其中每个 Ra 分子独立地选自由-C1-4-烷基、-C2-4-烯基、-OH、-OC1-4-烷基、卤代 -CF3、-OCF3、-SCF3、-SH、-S(O)0-2C1-4-烷基组成的组、-OSO2C1-4烷基、-CO2C1-4烷基、-CO2H、-COC1-4烷基、-N(Rb)Rc、-SO2NRbRc、-NRbSO2R、-C(＝O)NRbRc、-NO2 和-CN，其中 Rb 和 Rc 各自独立地为-H 或-C1-4烷基；和 Ar2 在权利要求中定义的化合物可用作 FAAH 抑制剂。此类化合物可用于治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、失调和病症的药物组合物和方法中。因此，这些化合物可用于治疗焦虑、疼痛、炎症、睡眠障碍、饮食失调或运动障碍（如多发性硬化症）等。
• PIPERIDINE- AND PIPERAZINE-1-CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE (FAAH) FOR THE TREATMENT OF ANXIETY, PAIN AND OTHER CONDITIONS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1836179B1

  公开（公告）日：2015-05-06
• US6218404B1
  申请人：——

  公开号：US6218404B1

  公开（公告）日：2001-04-17